Home › Marginal Zone Lymphoma › North Carolina
Pag-aaral pangklinika para sa Marginal Zone Lymphoma sa North Carolina
14 pag-aaral para sa Marginal Zone Lymphoma ang naghahanap ng mga kalahok sa mga site sa North Carolina.
Mga Lungsod sa North Carolina
Opisyal na teksto ng pag-aaral (English)
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Southeastern Medical Oncology Center-Clinton, Clinton
- Levine Cancer Institute-Gaston, Gastonia
- at 3 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT04840602A Study of ARC-02 in B-cell NHL
- Levine Cancer Institute, Charlotte
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT07691606Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- University of North Carolina at Chapel Hill, Chapel Hill
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06708897A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
- North Carolina Basnight Cancer Hospital, Chapel Hill
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT06860880Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- at 4 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 65 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT01137825Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Duke Univerisity, Durham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT04775745Study of SGR-1505 in Mature B-Cell Neoplasms
- Duke University, Durham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT05544019Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 20, 2026 · NCT04223765AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Duke University, Durham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 27, 2025 · NCT01137643A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2025 · NCT05780034Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.